Artrya Limited (ASX:AYA)
Australia flag Australia · Delayed Price · Currency is AUD
2.840
-0.220 (-7.19%)
Nov 17, 2026, 11:34 AM AEDT
← View all transcripts

AGM 2026

Nov 13, 2026

Summary

Five U.S. health systems had signed commercial agreements as operations shifted from R&D to commercialization. Priorities include onboarding customers, increasing plaque use and securing FDA clearance for Salix Coronary Flow, while managing integration and adoption pace.

Bernie Ridgeway
Executive Chair, Artrya

My name is Bernie Ridgeway, and I am the Executive Chair. Today's Annual General Meeting is being held in person at our offices here in West Perth, and we also have provided the ability for those not able to be here today to watch a live broadcast of this meeting via the Zoom webinar platform. Voting will only take place in person here today or via proxy and will not be possible online or through the broadcast. Today's meeting is being recorded, and parts of it, including my address and the CEO presentation, will be uploaded to the company's website and released to the ASX. For those attending in person today, we will have a roving microphone to ask questions at relevant times throughout the meeting. Please note that as Chair, I will not address questions until the relevant time in the meeting.

Those shareholders watching this meeting via Zoom will not have the ability to ask questions, but we gave the ability for shareholders not to be able to be here to submit their questions in advance of today's meeting, and we have received a number of those, and we will go through those later in the meeting. Voting today will be by way of poll on all items of business. I note that proxy votes must have been received by 11:30 A.M. on Wednesday, November 11, to be effective. Voting will take place in person only during this meeting. With us today is Namrata Gunawa from Automic, who will be acting as Returning Officer for the poll. Moving on, I note that a quorum is present, and I declare the meeting open. Before proceeding with formal matters, let me introduce my fellow Non-Executive Directors.

To my immediate left is Jacque Sokolov. Jacque is based in the U.S. And to Jacque's left is Jeff Le Benger. Jeff has been appointed during the year, and he is out from the U.S. as well. To Jeff's left is Mark Pitts, our Company Secretary. To my immediate right is Helen Kurincic. Helen joined a few months ago, and we are very pleased to have her on board as well. John Konstantopoulos, our CEO, and on the end, Clayton Hatch, our new CFO. And very pleased to have everyone here today joining us for the meeting. Apart from Kate Hill, she has got a family issue, a serious family issue in the U.K., and she is an apology for today's meeting. Mr. John Ward and Fran Arnold, representing KPMG, the company's auditors, are here should any questions or matters need to be directed to them.

As previously mentioned, voting today will be conducted by way of a poll on all items of business. Any shareholders, attorneys, proxies, or corporate representatives attending the meeting in person will have been issued a yellow voting ballot upon registration. If you have not registered to vote, please see the Automic staff at the entrance. In terms of the format for today's meeting, I intend to deal with the formal items of business, close the meeting, and then invite John to conduct his CEO presentation. At the conclusion of John's presentation, we will also take some questions. Before proceeding with the formal business of the meeting, I will now proceed with the Chair address, and I will keep it relatively short. I am sure people will be pleased to hear that. 12 months ago, I said that our focus had shifted to commercial execution.

I'm pleased to report that in FY 2026 and early in FY 2027, we've shown good progress on that commitment. We have signed multi-year commercial contracts with five U.S. health systems. We're in the early stages of a revenue-generating business. Our CEO, John Konstantopoulos, and his team have worked tirelessly building our commercial operations. John will talk to our progress and plans in his CEO presentation shortly. Today, I will focus on four things. One, the scale of the opportunity in front of us. Two, our commercial traction. Three, our strength and leadership to support our endeavors. Four, as I close, I'll confirm our priorities. First of all, the scale of the opportunity. Artrya is targeting a market in the U.S. that is large and growing every day.

The U.S. market for CCTA scans is currently worth around $ 4.4 billion a year and growing at a significant rate. The American College of Cardiology and the American Heart Association have recommended coronary computed tomography angiography, otherwise known as CCTA, as the first-line diagnostic test for patients with chest pain. This is further supported by the Centers for Medicare & Medicaid Services, otherwise known as CMS, when they announced last week an increase in the reimbursement for CCTA scans from the current rate of $356- $395 for coming to year 2027. In the same announcement, they confirmed the rates for plaque and flow assessments at $950 and $850 respectively. The significant growth represents an immediate and genuine challenge for all health systems in the U.S.

Volumes of scans are rising faster than the staffing and reporting capacity required to process them. The legacy approach of manual scan reads is simply too slow to keep pace. Hospitals are currently carrying the cost and burden of an overwhelming number of patients with chest pain and need a simple and highly scalable technology solution. We've built Salix Coronary Anatomy to address this problem. The key to that is we give hospitals a single enterprise-wide platform that simply and effectively manages all the workflow for the patients. We are not another single-point solution with an additional monitor like our competitors. By controlling the clinical workflow and offering highly accurate clinical insights in minutes is a game-changer. It saves time and costs, removes backlogs, allows the hospital systems to generate more revenue, and frees up doctors to better manage and help their patients. Next, commercial traction.

Over the last 12 months, we have focused on our three U.S. foundation partners and converting them into commercial reality. We have integrated Salix at Tanner Health and Northeast Georgia. Cone Health is progressing towards deployment. We also have a deliberate strategy to build our sales pipeline by converting SAPPHIRE research partners. We were thrilled to have Huntsville become the first of those to sign a commercial agreement. The strategy with our foundation customers is to have them fully integrated and using the Salix Coronary Anatomy Platform, Salix Coronary Plaque Assessment, and Salix Coronary Flow once it is cleared by the FDA. We are fortunate that all three are Category I codes and largely covered by the insurers. We continue to see strong inbound inquiry as the positive endorsement from our early customers permeates the healthcare sector in the U.S.

Today, we added HonorHealth as the first from this new group of potential customers, again significantly increasing the number of scans we will manage once Salix is deployed. We will continue to work hard to build our pipeline and convert additional SAPPHIRE partners into commercial customers. Across the three foundation customers, there is a common theme. Our Salix Coronary Anatomy Platform is revolutionizing their workflows, and the features of this platform and the plaque module win out over competing technology. These features were critical in being able to enter into commercial agreements with Huntsville and HonorHealth, and we will work hard to integrate Salix into their systems at the earliest. Our market advantage will increase further when Salix Coronary Flow is cleared by the FDA.

Adding to the scale of the commercial opportunity is an exciting product roadmap, which will use the Salix Coronary Anatomy Platform to further streamline cardiovascular care and improve patient outcomes. Leadership. This year, we have deliberately strengthened our board and leadership team. I was delighted to welcome two non-new Executive Directors, board members, I should say, who each bring impressive skills and backgrounds in healthcare technology businesses. Thank you to Jeff Le Benger and Helen Kurincic , who have settled in well and already brought strong insights into our board discussions. As new appointments, both Jeff and Helen stand for re-election at today's meeting, and we unanimously, I should say, support their re-election. We also strengthened our executive team with Clayton Hatch joining as a highly experienced CFO, particularly in the U.S. healthcare sector.

We welcomed a new Chief People Officer who also has experience with growing a company in the U.S. market. We added a General Manager of U.S. operations to lead our Atlanta-based customer success team, and we are actively recruiting high-quality healthcare experienced personnel to drive our growth in the U.S. Looking at our priorities, our short to medium-term priorities are very clear. One, deploy and maximize our technology into our existing customers. Two, grow scan volumes and revenues. Three, secure new customers from SAPPHIRE participants and inbound health systems. Four, and I'm sure you're all very interested in this, submit a high-quality FDA submission for the Salix Coronary Flow module. I would like to thank my fellow Directors for their valuable counsel and commitment throughout the year.

Additionally, on behalf of the board and all shareholders, I would like to thank John, the executive team, all staff, and consultants for their dedication and hard work in taking Salix from regulatory clearance into clinical use. It's not easy. To our shareholders, thank you for your continued support. To those who joined the register this year, welcome. We look forward to the next 12 months with optimism and a lot of excitement. I will now proceed with the formal matters for today. The purpose of this meeting is set out in the notice of meeting, which was made available to all shareholders on 14 October 2026. Unless there are any objections, I will take that notice as read. There are eight items of business for today, as detailed on the slide you should now be seeing.

Resolution eight, which was a special resolution dealing with changes to the company's constitution, has been withdrawn. We will present on individual slides the proxies received for each of the remaining seven resolutions. Proxy voting preferences, whether directed or left open for the nominator, representative, or Chairman, are available for inspection. Where I have been appointed proxy with instructions to vote in favor of a resolution, I will do so in accordance with the proxy form. Any undirected proxies assigned to me will also be voted in favor of the resolution. I do not intend to read each resolution in full as set out in the notice of meeting. As the resolution is displayed on the screen, I will invite questions from the floor, and I will be limiting questions to the motion under consideration. When asking a question, please state your name for the record.

If a question is asked which, in my opinion, does not relate to the motion which is before the meeting, I will rule that question out of order so, look out. As Chair, and in accordance with ASX governance guidelines, I will be calling a poll on each of the resolutions being considered. We will conduct the poll at the end of the meeting following the presentation of all the resolutions to shareholders. The first item is to receive and consider the financial accounts and reports for the financial year ended 30th of June 2026, consisting of the Director's report, the financial report, the Director's declaration, and the Auditor's report. It is not a requirement that shareholders vote in relation to the accounts. However, we are pleased to answer any questions relating to them.

As I mentioned at the outset, we have representatives here from KPMG with us, as is Clayton Hatch, our CFO. If you have any questions or comments, please put up your hand, and we will bring the microphone to you. There will also be time for general questions at the end of our formal business. Are there any questions or comments before proceeding? Given that there are no questions, we will move to the formal resolutions that need to be considered. Proxies received in relation to the formal resolutions are set out in the following slides. The first item requiring a resolution is the adoption of the remuneration report, forming part of the Director's report for the financial year ended 30th of June 2026.

The Corporations Act requires that a resolution be put to members to adopt the remuneration report as disclosed in the Director's report section of the 2026 Annual Financial Report. In accordance with the legislation, the vote on the resolution is advisory only and does not bind the Directors of the company. However, the Board will take the outcome of the vote into consideration when reviewing the remuneration practice and policies of the company. I now refer shareholders to the screen, displaying the resolution and the valid proxy results. As Chair, I now formally move that resolution one, the remuneration report, be put to the meeting in the form set out in the notice of meeting, and call a poll on this resolution to be held at the end of the meeting. Do any shareholders have any questions?

Okay, we'll move on to the second resolution, which seeks the approval of shareholders for the election of Dr. Jeffrey Le Benger as a director of the company. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results. I now formally move the motion that resolution two be put to the meeting in the form set out in the notice of meeting, calling a poll on this resolution to be held at the end of the meeting. Any shareholders have any questions on or comments in relation to the reappointment of Jeff? Welcome, Jeff.

Jeff Le Benger
Non-Executive Director, Artrya

Thank you.

Bernie Ridgeway
Executive Chair, Artrya

The third resolution seeks the approval of shareholders for the election of Ms. Helen Kurincic as a director of the company. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results. I now formally move the motion that resolution three be put to the meeting in the form set out in the notice of meeting, calling a poll on this resolution to be held at the end of the meeting. Do any shareholders have any questions or comments? Right, the votes are overwhelmingly in support of Helen's re-election, so welcome, Helen.

Helen Kurincic
Non-Executive Director, Artrya

Thank you.

Jacque Sokolov
Non-Executive Director, Artrya

All right. Mr. Chairman, it is my pleasure to entertain resolution number four. The fourth resolution seeks the approval of shareholders for the re-election of Bernie Ridgeway as director of the company. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results. I now formally move the motion that resolution four be put to the meeting in the form set out in the notice of the meeting, calling a poll on this resolution to be held at the end of the meeting. Do any shareholders have any questions related to the nomination of Mr. Ridgeway? Hearing none, congratulations, Bernie.

Bernie Ridgeway
Executive Chair, Artrya

Thank you, Jacque. The fifth resolution seeks the approval of shareholders for the approval to issue securities under an employee incentive securities plan. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results. I now formally move the motion that resolution five be put to the meeting in the form set out in the notice of meeting, calling a poll on this resolution to be held at the end of the meeting. Are there any questions from shareholders in relation to this resolution? Okay, we will move on to the sixth resolution, which seeks the approval of shareholders for the increase in total aggregate remuneration for non-exec directors. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results.

I now formally move the motion that resolution six be put to the meeting in the form set out in the notice of meeting, calling a poll on this resolution to be held at the end of the meeting. Are there any questions on this resolution? Okay, thank you. The seventh resolution seeks the approval of shareholders for the renewal, I should say, of proportional takeover provisions in the constitution. I now refer shareholders to the screen displaying the resolution in full and the valid proxy results. I now formally move the motion that resolution seven be put to the meeting in the form set out in the notice of meeting, calling a poll on this resolution to be held at the end of the meeting. Do any shareholders have any questions on this particular resolution? As I mentioned earlier, resolution eight has been withdrawn.

It was to deal with the changing of the constitution, and some of that wording around having online meetings was misunderstood, so we will redo that and bring it back to a general meeting going forward. That brings an end to the resolutions required to be voted on at this meeting. We will now conduct the poll. Please ensure that you have cast your vote on all resolutions by placing your voting cards in the ballot box circulating the room. I am sure there is one there somewhere. If you need a ballot paper, please raise your hand, and we will get one to you. Record your vote by placing a cross in either the for or against square on the paper. You should also print your name on the ballot paper. If you hold multiple proxies, please take this, and we will complete the information from the proxies.

Also, ensure that it is signed for it to be counted. I will now pause for your time to finalize the voting. [audio distortion] to the ASX this afternoon. At an annual general meeting, shareholders are entitled to ask questions or make comments on the management of the company. Do any shareholders wish to take advantage of this opportunity? I mean, this is a shareholders meeting, so if you have got any questions, we would love to answer them.

There will be questions, there have been some questions submitted, which we will answer post John's presentation, but if there are any issues in relation to the management of the company, then we are more than happy to take them at this juncture. Yes.

Andy Barrett
Private Investor

[audio distortion]

Bernie Ridgeway
Executive Chair, Artrya

You need the microphone so the people online can hear the question.

Andy Barrett
Private Investor

Andy Barrett, investor.

Bernie Ridgeway
Executive Chair, Artrya

We need to hold that closer.

Andy Barrett
Private Investor

I am interested to know what your view is on the biggest constraint rollout of technology that you are working with as a partner. What is the biggest challenge, and what steps is the board and the leadership of the organization taking to be able to address those constraints?

Bernie Ridgeway
Executive Chair, Artrya

Yeah, it is a good question. I will let John take most of that, but I can say that we are dealing with small. At the moment, we are dealing with reasonably small. The foundation customers are reasonably small by U.S. standards, but they are large by Australian standards. They do not move at the same pace we do. In relation to what we have approved to date, we have the platform approved, which is Salix Coronary Anatomy, and we have our plaque approved as well. Plaque only became a Category I code in January this year, so some of the hospital systems are, they are just getting to know, they are getting used to plaque and dealing with it. To be absolutely frank, it is slower than what we would like.

We just finished a board meeting prior to the AGM this morning, and one of the key issues is around getting faster adoption, getting the cadence of adoption up a bit, our foundation customers, and certainly making the integration with Huntsville and now Tanner Health, streamlining those as fast as we can to increase the number of scans available to us. It is a very big focus that we have. It is not something that we are blasé about. We are building out our U.S. team. John is actually now based in the U.S. for the has been for the last few weeks and will be for the next six weeks or so. He is actually flying back from the U.S. to attend this meeting this morning, because having him on the ground in the U.S., driving our U.S. team, integrating with our customers, is key.

That is John, you can probably put some more color around that.

John Konstantopoulos
CEO, Artrya

Yeah, I mean, Andy, it is a good question, but maybe just to put some perspective. I mean, we have effectively only been commercial since the beginning of this year, and we have got five customers, there is a fifth one today. I think saying slow, I think you have got to be reasonable, and also the expectation that we are setting ourselves, five customers in the space of 10 months, 11 months, I think is a massive feat for us to get where we are. What we really have to make sure is that we are setting the right foundation and the platform for us to excel at beyond that.

If we run too hard trying to get customer acquisition, and there is probably not one hospital system we do not have access to in the U.S., whether it is either through myself, Clayton, or Jeff and Jacque, we could get into any probably one, any one of those. But the balance of setting the platform, making sure that we are supporting our customers, onboarding them, generating revenue, is more important now while we set the base, and then accelerate post that, is going to be the next step for where we are as a company.

Andy Barrett
Private Investor

Sure. Can I just ask a supplementary question? [audio distortion] Okay. Supplementary-

Bernie Ridgeway
Executive Chair, Artrya

That is much better.

Andy Barrett
Private Investor

Yeah. Okay. Supplementary question. Has the board considered, A, introducing incentives for the customer leads? I know that they are organizational leads. Have there been surprises in resistance to change that those of you working on the coalface, as it were, have found along the way?

Bernie Ridgeway
Executive Chair, Artrya

Sorry, I did not hear the last part, Andy. Where is it about incentives?

Andy Barrett
Private Investor

Very rarely I get asked to speak louder. But the second part of the question was, have there been any areas or surprises of resistance to change in terms of workflow? The word workflow is used a lot in these meetings—

Bernie Ridgeway
Executive Chair, Artrya

Yeah

Andy Barrett
Private Investor

—and in documentations. Have there been surprises, and what have they been?

John Konstantopoulos
CEO, Artrya

Yeah, so the

Andy Barrett
Private Investor

The implementation and the sales process going forward.

John Konstantopoulos
CEO, Artrya

I'll go to the second part first. Then we just got out of a discussion around REM going forward. I think that will answer the first question. Workflow, you're right, is being used a lot. It's like AI, it's a big word. If I take it back to the challenges that the hospital systems are having across the board in the U.S. and probably here in Australia at the moment as well, is that the CCTA volumes are really growing rapidly. Cone Health, one of our foundation customers, is growing at 35% year- on- year. Huntsville is growing at 25% year on year. The 4%, 5%, 6% that we quote as industry growth is very conservative. We're seeing double-digit growth across the board.

The problem is that the hospital systems are being squeezed in their costs, but also how many doctors they want to get on board. Volumes are doing this, but doctors are staying that way. The reason I'm saying all of that is that workflow is a huge issue for them at the moment in the U.S. Dr. Jeff Le Benger made a comment in the board meeting earlier is that we can talk about clinical benefit, we can talk about workflow, but one of the biggest things they care about is make them faster, make them more profitable, and that's effectively what we're doing with the platform.

Andy Barrett
Private Investor

Making it faster. [audio distortion] I'm sorry, John. You said making it past the-

John Konstantopoulos
CEO, Artrya

Faster

Andy Barrett
Private Investor

last sentence.

John Konstantopoulos
CEO, Artrya

Faster. Efficiency, basically faster. Yeah, it is all right. Yeah. Speak louder.

Bernie Ridgeway
Executive Chair, Artrya

Sorry, the—

John Konstantopoulos
CEO, Artrya

The next one.

Bernie Ridgeway
Executive Chair, Artrya

I am not sure I understood that question. Was that incentives around our staff?

Andy Barrett
Private Investor

No, incentives for the customer to be able to change work and work practices.

Bernie Ridgeway
Executive Chair, Artrya

Yeah.

Andy Barrett
Private Investor

Whilst, it's a bit like playing with the man who's building it.

Bernie Ridgeway
Executive Chair, Artrya

Providing incentives to customers is not something we do. You've got some compliance issues around that, particularly around the Sunshine Act, which is very active in the States. And there is a massive amount of compliance that we need to be aware of. It's really around, and our approach has been around demonstrating the benefits of the workflow. I'm using that word again, but it is seriously a platform that makes them more efficient, takes that cost out, allows them to generate additional revenue. We've been helping them with that. And that's one of the reasons they adopted the software in the first place. The other thing that we haven't mentioned, it does come down to training the cardiologists and the clinicians about the features available with the platform and the plaque assessment and eventually the flow assessment.

The incentives is off the table. Certainly, we incentivize our staff to be able to do better work and more immediate and those sort of things, better the outcomes. But in terms of our customers, really it's around demonstrating the benefits of using the system, because they don't want another point solution. They do want an enterprise-wide workflow solution. But it's really around getting adoption with the cardiologist and the training and train the trainer and those sort of things, which is what we're actively involved in on a day-to-day basis.

John Konstantopoulos
CEO, Artrya

And just on the incentive as well for our customers, the incentive is really around how much money they make or save using a platform like ours. We have a very simple tool that looks at their scan volumes, compares our pricing against our competitors' pricing, assuming that our competitors are in the system, how many more scans they can do per day, and how many more patients they could send on for downstream procedures. If you take a hospital system like Huntsville that does roughly about 10,000 scans a year, if you take those three pillars, it is around about $ 4.3 million in opportunity for them every year. That is a huge incentive for a cardiovascular service line that drives margin for all the other service lines within the hospital system. We do not need to incentivize them.

There is already that incentive just using the platform.

Jacque Sokolov
Non-Executive Director, Artrya

The one thing that I think we have to keep coming back to is AI-enabled imaging, such as CCTA, is the right thing for the patient. At the end of the day, all these financial discussions are important, and your board is charged with fiduciary responsibility of optimizing shareholder value. But if it does not benefit the patient, we are in the wrong business. This is transformative technology that benefits the patient.

Bernie Ridgeway
Executive Chair, Artrya

Any other questions from the floor?

Speaker 7

Hi, guys. Northeast Georgia sounds really exciting, and the disclosure around that is really interesting. I was just wanting to get a bit more color on exactly how that program work's going and how we can expect that to evolve in the near term.

John Konstantopoulos
CEO, Artrya

You're talking about HonorHealth or Northeast Georgia?

Speaker 7

Northeast Georgia.

John Konstantopoulos
CEO, Artrya

The existing foundation customer?

Speaker 7

Yeah, that's right.

John Konstantopoulos
CEO, Artrya

Yeah.

Speaker 7

Yeah, exactly. Yeah, just I think in the disclosures, talk about it's underway.

John Konstantopoulos
CEO, Artrya

Yeah.

Speaker 7

Just wondering what that means in terms of practicalities and

John Konstantopoulos
CEO, Artrya

Yeah

Speaker 7

how we think about leading and finalizing that—

John Konstantopoulos
CEO, Artrya

Yeah

Speaker 7

—commercial arrangement.

John Konstantopoulos
CEO, Artrya

No, it's a good question, Andrew. We've integrated into their main campus in Gainesville. They've got a second campus in Braselton, which we're going through the training with the doctors and onboarding them at the moment. That's really getting them used to Salix, letting them use it across the board. And we get all the volumes across both hospital systems in Salix already. The main thing for us really now is to make sure that we're giving them comfort around using the platform, but also that they're using plaque. And one of the key things, and we see that with varying levels of hospital systems, is that some are very attuned to what to do with plaque when they get it. Others are not sure which, because it's so new within U.S. healthcare. With Northeast Georgia, that's more the latter.

What we've put in place is, we call it a plaque impact program, and it's really getting key opinion leaders to help and guide the doctors that report plaque in Northeast Georgia. Once they've got that patient that's got a plaque on the coronary arteries, make a decision on what to do with that plaque and how to treat them going forward. And that, our view, and strong view, is what's going to drive adoption going forward. And to Jacque's point, that's what gets better patient outcomes, is once they know what to do with the plaque when they find it and treat them more effectively, that's going to be a better outpatient outcome. Northeast Georgia is progressing quite well, but it is slower because of the doctors there wanting to know what to do with plaque when they get it.

Bernie Ridgeway
Executive Chair, Artrya

John, just following on from that, do you want to make a comment about Cone and their approach?

John Konstantopoulos
CEO, Artrya

Yeah. Cone.

Bernie Ridgeway
Executive Chair, Artrya

Cone, the third 10th of the customer.

John Konstantopoulos
CEO, Artrya

Yeah. I will use Cone and Huntsville because they are on the other side of the spectrum. You have Tanner, which probably sits. You have Northeast Georgia that are already trying to figure out how to use plaque. You have Tanner that is actively using Salix, and their plaque volumes are starting to increase because they are now getting comfortable with it.

Then you have Cone and Huntsville that are on this side of the spectrum that they have very, very strong clinical leadership within the hospital systems that have understood plaque and used plaque aggressively within the hospital systems. They do not worry about streamlining their reimbursement or about pre-authorization. They just click the button, get the plaque results, and treat accordingly. We have two varying levels of hospital groups that we deal with, one that are a little more immature and others that are very mature and have high volumes.

Those ideally are the ones that we want to keep on getting. Cone and Huntsville are going to be really good to work with because there will be less of the education from the clinical perspective, but more education on how they use Salix to make themselves more efficient.

Bernie Ridgeway
Executive Chair, Artrya

All right, Andrew, are you satisfied there? Good. If there are no further questions, that concludes the formal part of the meeting. As mentioned earlier, the results of the AGM will be announced to the ASX later today and placed on the website. I now declare the meeting closed. We will ask John to provide a business update, as we said earlier. Over to you, John. See if this works. Now we are getting onto the interesting part of the meeting.

John Konstantopoulos
CEO, Artrya

Is it me or is it you? It is Jacque? That is me. Great. No, thanks, Bernie. I appreciate everybody being here today as well, and thank you shareholders for your continuous support. One of the things that I just want to really focus on is that we have really transitioned away from being a technical R&D company to really shifting to commercial earlier this year. It has been a big year for us where we have been heavily focused on setting the base of the company. From that base that we are trying to set, as I mentioned earlier, that is going to give us the ability to really launch off as we go into the subsequent years with this business.

Today, I really just want to give an update on where we are, what we have achieved this last 10 to 12 months since the previous AGM.

Just see if this works. It does work. As a quick summary, and Bernie has already mentioned it, I mean, we are tackling one of the largest causes of death globally. Heart disease kills more people than all cancers combined. Every 40 seconds, someone in the U.S. has a heart attack. Every 12 minutes here in Australia, someone dies of a heart attack. If you think of how long we have actually been sitting here, what that actually means from those stats and how many patients have already been impacted just in this last half an hour.

Really why we have built this differentiated platform that focuses on taking a CT coronary angiogram and in real time and at the point of care, being able to show a doctor where the plaque and where the disease is so they can make a better informed decision on how to treat that patient, but also help them work a lot faster and increase their throughput. I will not use workflow, Andy. I will use throughput going forward. We do have both our platform and our plaque product cleared by the FDA, and we are seeing substantial interest just on those two. As you saw probably earlier today, we announced HonorHealth. That was another testament to customers in the U.S. wanting to get the benefits of throughput and efficiency from the platform, but also use the plaque product because they see an opportunity to better patient care.

We are working very closely with our SAPPHIRE partners at the moment, both from a clinical perspective, and we are really trying to get that study moving. I have personally slowed that down just a little bit so that we could focus the team on SCFs so that we can get that study going and then we can get that submission in. But the SAPPHIRE study is effectively a two-part process for us. One is being able to judge the future of heart care so that we can predict risk of patients in the future, specifically in women. There is a big focus in women with coronary artery disease, so we are really trying to push forward with that.

But the second part to it, which is really a major commercial driver for us, is it is our big go-to-market strategy in the U.S., where we are using those six foundation, sorry, those six SAPPHIRE partners as a pipeline generator for us to really drive our growth without having to put a big sales team on the ground. Huntsville, as Bernie said earlier, is a real testament to that go-to-market strategy working. With the other five, we are in varying stages of commercial maturity with them as well. I do want to talk about HonorHealth, and Jacque, I would not mind some color from your side because you are there with them as well. But for us, HonorHealth is a significant achievement. We announced them earlier this morning.

They are our first inbound customer, which is a good showcase for what we are looking to do in the U.S. beyond just the SAPPHIRE partners. We are getting quite a lot of interest and inbounds coming in, and HonorHealth is one of those customers. They are in the top 100 health systems in the U.S. In fact, I think they are the number 77th largest hospital system in the U.S., which, if you are considering how big U.S. healthcare is, number 77 is a substantial hospital system. They serve over 5 million people. They have got nine acute care hospitals. They have got 40 heart care locations across Arizona, and they are really focused on driving better patient care.

Part of this agreement that we have signed with them, not only to use Salix within their hospital from a platform perspective and plaque perspective, but they are really working closely with them to build a center of excellence where they want to use AI-enabled CCTA assessment, i.e. Salix, in addition to high-quality imaging photon-counting scanners to build a center of excellence and really lead in Arizona, and ideally be a platform across the U.S. on what good looks like. So for us, it is a major achievement. The agreement does not look any dissimilar to the others that we have. We price that with the Salix Coronary Anatomy Platform at roughly $ 0.5 million. That also, as part of the contract, in addition to the $ 0.5 million, includes per-scan clicks with plaque, as well as per-scan clicks with flow when it gets cleared.

The upside for HonorHealth, similar to Huntsville Health and the others, is substantially higher than the half a million dollars. We have just focused heavily on the subscription fee for now and priced the per click in that. Jacque, I do not know if you have anything to add.

Jacque Sokolov
Non-Executive Director, Artrya

I will make a very short comment. Thank you, John. HonorHealth views Artrya as the crown jewel in a cardiovascular center of excellence, and basically, they have asked us to help them vision in relationship to what the future of cardiovascular care should look like in a large health system. They are about a $6 billion system in a regional environment, Arizona. They also have a partnership with what is called ASU Health. ASU Health is the first academic medical center that actually awards an MD degree as well as a master's in AI engineering. So all medical students going through will have an AI background as well. This is a wonderful opportunity for us to optimize all the issues related to AI-enabled technologies and hopefully basically move the needle in relationship to how clinical care is improved going forward. So we view that as a very positive development.

John Konstantopoulos
CEO, Artrya

Thanks, Jacque. So it is a testament to our strategy going forward. We are getting the interest now, not us pushing out. There is interest coming in now. So it is a focus point for us to start leveraging that going forward beyond just the SAPPHIRE partners and build that pipeline beyond just SAPPHIRE. Going back into this last 10 to 12 months in the last financial year, I am actually fortunate enough to say five. It was four yesterday. So we have got five customers that have now signed up within the U.S.

If you look at what HeartFlow does and how they account for how many hospital systems they serve, we have 41 hospitals now as part of the five hospital systems that are part of the group. So that is a substantial increase from where we were before. We converted our first SAPPHIRE partner. We have started generating our first U.S. revenues.

Our plaque volumes are starting to increase since we brought in the first phase of our pre-authorization process. The SAPPHIRE study has been launched as well, and we are progressing through that. We also got the plaque clearance from the FDA this financial year. A big focus for me, and that is partly why I am in the U.S. at the moment, is making sure that our U.S. operations is really moving forward.

Probably, Andy, to your question, how do we accelerate, is getting the team focused in the right areas there, which is getting the customers on board that we already have, generating revenue from them, increasing plaque utilization, and then converting some of the other SAPPHIRE partners, as well as the inbounds that we have as well. As Bernie mentioned earlier, we have also strengthened our leadership team with Clayton joining, so I am very thankful that Clayton has joined.

I've shrunk about three inches over the last year, and I've probably grown another inch since he's come in. Thanks, Clayton. You've made my life a little easier. Clayton brings a lot of experience. If many of you know Pro Medicus, he's been a CFO there for many years. We're thankful that he's, and very fortunate for him to have joined us and with the experience that he brings. He and I are working very, very closely at the moment on a number of initiatives. As Bernie also mentioned, Dr. Jeff Le Benger and Helen Kurincic have joined the board, and we've now also established two committees, both the Rem and Nom Committee, as well as the Audit and Risk Committee, as we grow up as a company going forward as well. From a commercial perspective, we have Tanner fully live.

Our focus with Tanner is now driving plaque utilization, and we are starting to see that. We saw part of that in the last quarter, in the last quarter release, where we've started seeing the numbers increase, and we'll start seeing that going forward as well with a lot of the initiatives that we'll be putting in place. Northeast Georgia, as I mentioned earlier, their first hospital, Gainesville, is already integrated, and Braselton now, we're onboarding the remaining doctors there. Cone Health, we're working through the whole pipeline of getting that deployment done with them, and that's working with the IT team, the same as Huntsville. We're working with the IT team to find what the kickoff date looks like for that so that we can get them integrated and going live as soon as possible. HonorHealth, obviously, first, we announced that today.

There's a bit of work for us to actually get that work done when that integration happens. I do just want to go back to the issues that our customers are seeing, and I know workflow is a word used a lot, Andy, but it is a substantial issue in the U.S. Coronary artery disease, as I mentioned, large cause of death. CCTA is becoming a first-line tool within the U.S. hospital systems. They are moving away from stress testing, they're moving away from nuclear imaging, and they're moving away from SPECT to CCTA for all the reasons we've mentioned in the past. It's a faster turnaround time, the spatial resolution's better, and you can actually see the disease on the coronary arteries.

The challenge with that, though, is because of that major shift, we've seen a huge growth in volume, but doctor capacity is not increasing with that volume, which means that the doctors and the hospital systems are severely stretched at the moment, and backlogs are starting to increase. One of the big hospital systems we deal with mentioned to me earlier this year that over probably a course of about three months, they scanned about 600 patients and had not yet read all 600 patients, which is an issue on its own right because those patients are just not getting care. It just gives you an indication of how stretched they are. Which is really where our focus is as a platform. The platform brings a whole bunch of singular solutions into one dedicated operating reporting system for reading coronary CT tests.

That platform becomes their reporting system of truth for them. They remove all the other manual processes or systems that they have, and they replace it with Salix, which is what happened with Tanner. They replaced Philips. That has happened with Northeast Georgia, where they are replacing TeraRecon. It will happen with Cone, where they will replace TeraRecon, and Huntsville, same thing.

That allows us, because of how we price, but also our turnaround times, allows them to become a lot more profitable and generate more revenue. But the most important thing is, yes, hospital systems want to generate more revenue and they want to have more margin, but we also want better patient care. Because we can turn around the results a lot faster, they can also treat the patients a lot faster and get them to care, whether it is invasive test or lipid therapy test, a lot faster as well.

It is a big focus for us, making sure that patients are cared for well. I will not go through this slide here, but what it shows is that we are taking a very disparate number of solutions at the top swim lane and bringing that into one single platform. Hospitals are inundated with point solutions at the moment, and they want to bring that all into one single platform, which is what really is a value driver for us. Where we are at the moment, we have the three foundation customers all in that central area, that Midwest South area, so Georgia, North Carolina, and now Alabama with Huntsville. That is a two hours drive from Atlanta.

You can see all the other partners that we have are all in that Northeast, Midwest, South belt, which is really why we put our customer success and our general manager in the U.S. focused in that region over there, because it is a major opportunity for us to be focused and drive opportunity. HonorHealth is in Arizona, so that is the first one that is away from that, and we are starting to see other interest from the West as well. But a big focus for us is to stay East and really get our team focused on that as well. Our SAPPHIRE partners are in the East as well, or in that East Midwest belt, as well as some of the inbounds that we have. They are all focused on that Midwest East belt.

I will not go through the SAPPHIRE study because we have gone there, but just want to talk about commercial execution. As I mentioned earlier, a big focus for me and the team on the ground over the next few months and going forward is making sure that we have all our foundation customers onboarded and live so that we can start getting them using the platform, but also increasing our plaque utilization. That is really going to be where our revenue drive comes from, is getting them using the software from a platform perspective, but really clicking on the plaque button because of the pricing and the revenue we get from that, but also the better patient care. Then what I really want to get moving forward as well is that we start securing other healthcare systems, bringing them on board, and really getting them onboarded.

Now, one thing I am very focused on is that what we don't want to do is accelerate too fast beyond what we can actually support. So, making sure that we've brought the current systems on board and making sure that they're successful is very important for me first before we scale from there. The one question everybody is very much focused on is Salix Coronary Flow. I do just want to iterate, all five customers that we currently have have signed up with Artrya and Salix without the Flow product being there. They all see the benefit of the platform from efficiency and from throughput perspective. They all see the benefit of the platform and plaque from a clinical benefit perspective, and they all see the benefit from that with regards to margin optimization with each hospital system. Do they want Flow?

Of course, they want Flow, but that's not stopping them from using a system like ours and waiting for Flow. Yes, we are moving down the pathway to get Flow submitted and cleared, but we're getting a lot of interest from hospital systems without Flow at the moment. That being said, just as a recap, we went through the Q-Sub meeting in October last year. We've completed the module and the calibration of that, and we're going through the FDA study process at the moment. As I mentioned at the quarterly, one of the things that we've done is brought in a reader study to make sure that we cover all known and potentially unknown areas that the FDA may ask of us when we submit so that we have a very solid and complete submission submitted to the FDA.

The reader study is our process of making sure we're doing that properly. Once that is completed, we'll submit the 510(k) submission, and then we'll go through the normal 90-day process, assuming there's no questions. If there are questions, they stop the clock, and then they give us time to answer those questions. Once we've submitted those answers back, they start the clock again. It is very normal for the FDA to stop the clock and ask questions, because effectively, they're getting a bunch of paper like this with all the information about our product that we know really well, and all the information that we have a lot of comfort on, but they've got to read that all for paper.

When they do stop the clock, it's usually them wanting to know or if there's potential confusion on what's in the paper that they want clarification on. When the clock is stopped, that's not a bad thing. They just want clarification on that. Let's skip that slide over there. Going forward, a big focus for us is making sure that we complete the deployment of our existing customers. Making sure that the remaining part of Northeast Georgia is scaling, making sure we get Huntsville and Cone onboarded and then scaling with them, and then the same thing with HonorHealth. We want to grow our plaque usage and utilization, and it's a big focus of ours with our U.S. team. As I mentioned, we've put a plaque impact program in place that sets the foundation of how we're going to do that in the U.S. as well.

We're building our customer base, both from a SAPPHIRE perspective, but also inbounds, and we'll start converting those over time. Then making sure that we get the Salix Coronary Flow product submitted and cleared by the FDA, which will wrap up the final piece of our coronary artery disease assessment platform. Obviously, there are other things, as Bernie mentioned, from a roadmap that we're looking at, such as structural and a few other things. But from a coronary artery disease, that wraps everything into one. Then really start building the clinical credibility in the U.S. by having some very focused studies that show the benefit of plaque, how accurate it is against invasive tests, but then also really scaling our U.S. operations as we bring more customers on board and not doing that too early.

Just to summarize, we believe we've got a really strong platform to grow and build a really successful business because of the four buckets that I can show you. You can see at the top over there, the one integrated platform is gaining a lot of interest from hospital systems because they bring everything into one. The real-time point of care for all the reasons I mentioned, better patient care, faster patient care, as well as improved throughput, is a major value proposition of ours. It's streamlining the workflow. It's making it a lot more efficient. Doctors are able to read in their normal day now and not reading at night. One of the stats we got from Tanner Health is that it's improved their efficiency by 50%, not 15%, 50%, which is a substantial increase in efficiency improvement. We are starting to see substantial improvement there.

Then, as I spoke about ad nauseam, is that the strong hospital economics is important because of the regulatory environment in the U.S., where they are under heavy pressure to reduce cost, they're under heavy pressure to grow their margins, and make sure that they can sustain themselves as a hospital system. I'll stop there. I want to thank you all again for being supportive and listening to my questions, and I do have some questions over here from one of our shareholders.

Bernie Ridgeway
Executive Chair, Artrya

I'll kick off while you're trying to. There are some questions that have been lodged by the online team. The first one, "Can you tell us about how Salix learns and becomes more accurate over time?" John, do you want to take that?

John Konstantopoulos
CEO, Artrya

Yes, I can. Sorry. Every time one of the other benefits we have compared to our competitors is that because the platform gets all CCTA scans, we get all that data, so our database keeps building over a period of time as we get more customers on board. But every time a doctor makes an edit or a click, we get that information in the background, and we are able to use that information in a very specific way, in a regulated way, to improve the product. We cannot just keep improving it as we get the data. The FDA regulates that for us. We have to make sure that we are validating the data, that it is clinically accurate, and that we can improve the product, and that we are meeting our indications that the FDA cleared us for.

Yes, we are improving the product by getting more and more data, and we are improving the product without that data with the backend R&D team that we have over here. They are consistently improving the product as well. But when we do get data from hospital systems, it has got to be a very specific and regulated pathway.

Bernie Ridgeway
Executive Chair, Artrya

Okay, moving on. Can you quantify the increase or the actual number of plaque scans at Tanner in October and November since the pre-authorization upgrade? It is a pretty hopeful question.

John Konstantopoulos
CEO, Artrya

Yeah. No, look, as we have always said, we are not going to give those numbers out at detail at a singular level just now. We will wait for more broader adoption and utilization going forward, and then we will start looking at what that looks like and what numbers and metrics we do announce. But we are seeing utilization increases with Tanner, and that is continuing to increase with the work we are putting in as well.

Bernie Ridgeway
Executive Chair, Artrya

This is a pretty topical one as well, John. Can you please explain how long you expect it will take to integrate and go live with new customers such as Huntsville Health after you've signed the contract? Is this changing after the first few integrations you have completed? So, are we learning from the integrations to put into practice at Huntsville?

John Konstantopoulos
CEO, Artrya

Yeah, we're definitely learning from those integrations, and we're consistently fine-tuning our approach in our integration onboarding process. We're very much dependent on the hospital system and the IT teams over there. They've got their processes that they've got to work through, so what we try to do is make sure that we're efficient as possible once they engage, and we try and make sure that we're dragging them across the line. We've got to deal with how they approach each project and how they implement and integrate each project. It's a hard question because how long is a piece of string? Some hospital systems take a lot longer, others go a lot faster. From our perspective, what we're trying to do is make sure that we're pushing them to go a lot faster as well.

Bernie Ridgeway
Executive Chair, Artrya

I mean, just on that question, with our foundation customers, these are some of the things we can't control. One of them was going through putting a new PACS system in place.

John Konstantopoulos
CEO, Artrya

Yeah.

Bernie Ridgeway
Executive Chair, Artrya

Another one was going through an acquisition. So, they're the sort of real-life issues that we're encountering—

John Konstantopoulos
CEO, Artrya

Yeah

Bernie Ridgeway
Executive Chair, Artrya

—in dealing with customers that are running a business on a day-to-day basis. Couple questions here on SAPPHIRE, John. One is, when can we expect the participants to begin analysis in the study, and what is the update on timing to get the first set of results?

John Konstantopoulos
CEO, Artrya

Yeah. We're working through the protocol and ethics at the moment with all the hospital systems. Some will go a lot faster, some will go a lot slower, just based on the type of centers they are. The academic medical centers, like Mass General, just who they are inherently slow. Some of the other ones are faster. Once that's completed, we'll start the activation of each of those sites from a data perspective and bring that in. As that data starts coming in, we'll start looking at processing those scans, and then looking at when we actually want to put results out. There are a number of conferences next year that we want to be at, and ideally would like to have some results, even though initial, to put into those conferences so that we can present there and have abstracts going into those conferences.

But as we get close to that, we'll know more from them.

Bernie Ridgeway
Executive Chair, Artrya

On the other question on SAPPHIRE, how advanced are commercial discussions with the other five SAPPHIRE sites, and are you planning to sign any of these in the near term?

John Konstantopoulos
CEO, Artrya

Varying levels of maturity. That's my standard statement.

Bernie Ridgeway
Executive Chair, Artrya

Yeah. We're obviously engaged with all of the SAPPHIRE partners in various levels of negotiations and work programs that are going on there. Obviously, the larger ones take longer, but you've got to start down here to be able to get them to commercialize in the future. Yeah, they're a major potential revenue source for us, and we're certainly

John Konstantopoulos
CEO, Artrya

[audio distortion]

Bernie Ridgeway
Executive Chair, Artrya

We're pushing hard there. I think one of the things that we need to remember is, we signed our first commercial customers in December last year, and if you think back to Pro Medicus, in the early days of Pro Medicus, they might sign one customer a year back in the same stage that we're at.

John Konstantopoulos
CEO, Artrya

Which I'm—

Bernie Ridgeway
Executive Chair, Artrya

obviously, we're smaller, and the hospital systems we're dealing with are on the small side at the moment, but certainly some of the SAPPHIRE partners are large. We've said previously that across all of the six SAPPHIRE partners, there's $ 340 million worth of potential revenue there. If you add a little bit of inbound in, we don't have to look any further around the U.S. healthcare system to be able to build a really good business. We are in the early stages of building a serious business here, and it just does take time. We wish things could go faster, and we're certainly focused on that, but there's a fantastic lot of white space in the U.S. for what we're doing, and we're getting after it as fast as we can.

We want to make sure that with these new hires that John's senior people in the U.S., we put on the right people, and really turbocharge the growth going forward. We don't want to overpromise and underdeliver. We're certainly running behind schedule where we thought we'd be. Some of that's our fault, some of it's stuff that we can't control. We are building a serious business. The other question I've got, John, I think you've already answered in relation to progress on SCF and the filing of that 510(k) application.

John Konstantopoulos
CEO, Artrya

Yeah. We are working heavily on that.

Bernie Ridgeway
Executive Chair, Artrya

Yeah.

John Konstantopoulos
CEO, Artrya

We will let the market know once we submit, but rest assured that the whole company is working on that and heavily working on that at the moment to make sure we put a strong compliance submission in for SCF.

Bernie Ridgeway
Executive Chair, Artrya

I think they are the ones that have come through to me as chair, so i think you had a—

John Konstantopoulos
CEO, Artrya

I have got a couple here. One of the questions was, five questions here. Can you tell us if the second stage of the pre-authorization process is complete? If not, when will it be? Is at least some of the pre-authorization process active with any or all of the three foundation partners? The second phase, that is still in work. That will come at our next product release, and that is being planned, that has been planned, and we are busy pushing through with that at the moment. The phase one has been implemented at Tanner Health. That is being implemented at Northeast Georgia at the moment. Cone Health and Huntsville are not live yet, but once we start that process with them, then we will do the phase one with them as well.

A big focus is making sure that the doctors have comfort that when they do click the plaque button, that the hospital system is getting reimbursed for that. Phase I does allow that. Phase II streamlines all of that with the full automation. The second question, as Tanner further advanced than Cone Health and Northeast Georgia, can you provide some detail as to plaque versus SCA ratio, or if it is at the expected 65%? As I mentioned earlier, we are seeing growth in our plaque utilization. We will not announce those numbers yet, but that growth is increasing. Are any of the larger groups close intending to conducting a pilot trial of the Salix platform? If I look at the SAPPHIRE groups, we are early with some of them with regards to pilots. Others are well progressed with pilots.

We are not just standing still and trying to do things in a linear fashion. Huntsville hopefully was a testament to that because we committed that to the market next year. We got that basically a year earlier. HonorHealth, similarly, there is a lot of parallel pathways we are pushing both from a SAPPHIRE perspective, but also a pipeline perspective that is progressing at varying speeds.

The last, that is one of those. Second last question, "The SAPPHIRE study started some time ago. Can you talk to the level of scans put through?" I think I have answered that one already. We are going through the protocol process of that one. "How are you going with the Perth Australian-based CTO?" We are progressing that one. Nadine, our Chief People Officer in the corner there, she is hiding there at the moment. She has just joined us recently. She is helping heavily with that process.

We are trying to find someone that does have healthcare experience. To be honest, in the past, I was probably trying to find a unicorn here in Perth that had deep AI expertise, but also healthcare expertise and based in Perth. I think that is a bit of a pipe dream, to be honest. I have shifted the way of thinking that where if we can find a strong CTO that has broad understanding of healthcare and technical and able to drive our R&D and product team, that is the better pathway to go, and then they can put leads under that person that have the deep experience that we need. That is pushing forward at the moment.

I am very focused on that specific role because we have got a very strong team over here that we want to make sure we have the right person that comes in and leads that team. Apart from that, Josh, yes, I will go for a beer with you in January.

Bernie Ridgeway
Executive Chair, Artrya

Is that it, John?

John Konstantopoulos
CEO, Artrya

Yeah, that's it.

Bernie Ridgeway
Executive Chair, Artrya

All right. So any more questions from the floor before we close? Oh, a couple of hands have gone straight up there.

Speaker 8

Bruce.

Bernie Ridgeway
Executive Chair, Artrya

Yeah.

Speaker 8

John, with your SAPPHIRE partners, are they using Salix in the same way they would if they were a commercial partner? Is it the case, however they're using it, that when they come on stream as a commercial partner, their conversion to revenue generating and processing the scans is going to be much faster than for a cold start like HonorHealth?

John Konstantopoulos
CEO, Artrya

Yeah. Look, it does. Can everybody hear me okay? I do speak a little softly sometimes. Look, the process we set up with SAPPHIRE is to do exactly that. What we've seen with the hospital systems, I'll take Ascension as an example. The way they work is, for study or commercial, they want the doctor to do the pilot first. Once that is approved, it then goes to the technical committee, and then they do a more formal integration, and then they do a clinical pilot in situ to see what that actually means for them from a commercial perspective, from a clinical perspective, and from a workflow perspective. SAPPHIRE is trying to bridge that gap between just the doctor looking at the screen to having some level of integration so they can get scans coming in, and they can also test that clinically.

Yes, it does help, but I do go back to one of the earlier statements that I made is that once that one piece is done, we still have to go through all the other IT pieces that the hospital system has in place as well. But it does solve that one sliver.

Bernie Ridgeway
Executive Chair, Artrya

There was another question up the back there.

Jeff Coles
Private Investor

Hi, John. Jeff Coles here speaking. Thanks for a great presentation. It has been a big year, so most of us appreciate it. You have stressed that you need to hasten slowly and make sure that the customers that we have got are well-serviced. I fully endorse that. I am interested in what the company or the board's aspiration is as far as when are you going to enter the scaling phase? I mean, we are clearly not in that now. Are we talking one year, three years, five years? What is the sort of generic feel for it?

John Konstantopoulos
CEO, Artrya

Yeah, look, I think the answer is as soon as we have the foundation customers in Huntsville up and running and we are scaling with them, we will really start scaling from there. But again, it will be a targeted scale. What we do not want to do is take a shotgun and shoot and see where we land in the U.S. because that, as I mentioned, what I do not want to do is have 20 Northeast Georgias that are immature with regards to plaque, and then we have got to battle through that, as opposed to having 20 Cones, Huntsvilles, HonorHealth as an example, that are more mature and really want to drive innovation and usage of that. So we are already scaling in the background.

As I mentioned, HonorHealth, we have said that we are going to take it slowly. HonorHealth came as an inbound. We are getting a lot of other inbounds coming in.

SAPPHIRE, we are ramping through that as well. But it is making sure that we have got the people on the ground to manage that scale as we go forward, because if I sign 20 customers up now, you know, it just becomes a lot harder. I am not saying it is a happy problem to have, do not get me wrong, but you do not want to go break the business because credibility in the U.S., especially in cardiology, is incredibly important. But the answer is we are scaling.

Bernie Ridgeway
Executive Chair, Artrya

Yeah. I think the other key thing, Jeff, is building a solid platform

John Konstantopoulos
CEO, Artrya

Yeah

Bernie Ridgeway
Executive Chair, Artrya

to be able to scale off. I can tell you now, across this table, if we could scale tomorrow, we would.

John Konstantopoulos
CEO, Artrya

Yeah.

Bernie Ridgeway
Executive Chair, Artrya

It just has to be done in a managed way. Right.

Jeff Coles
Private Investor

Yeah, I agree.

Bernie Ridgeway
Executive Chair, Artrya

Yes. No, it is a very good question, and it is one we get all the time. If there was a magic bullet that we could use, we would certainly use it, but there is not. You have just got to go through the process. Building good people on the ground in our team in the U.S. is critical. You know, getting the training and the handholding with our customers is critical. Working with some of these SAPPHIRE partners to get them over to commercial customers is critical. Everything we are doing is important. Could it go quicker? We would love it to go quicker.

We are not sitting here as a board saying, Look, you cannot spend the money, you cannot do this, you cannot do that. We want to spend the money, we want to scale, but we have got to do it in a managed way, and not let the company fall over. We have seen history books littered with that, where they see this great opportunity, try to go too fast, and they fall over. We would like to be going faster, but it takes, I said in my address, is really taking it from clinical to commercial is a big step. We are not riding into the U.S. on a white horse saying, Look, we are the solution to everyone's problems. We have got to make sure we justify our presence to the hospital systems, demonstrate the worth of the technology, and so on.

To this day, we have not had anyone say, "We do not believe in that technology. It is a load of rubbish. Take it away." We have not had anything like that said to us. Everyone loves it when they see it, but you have got to deal with a number of different stakeholders within the hospital system, the CMO, the CFO, the CTO, the CEO, because what we are putting in place is an enterprise-wide solution. Someone down in the bowels of the organization cannot say, Oh, look, this is a great point solution. Let us do it. This is an enterprise-wide solution, so it has to have the buy-in from all the key players. It does take time.

John Konstantopoulos
CEO, Artrya

Yeah, I mean, just to wrap that up, you've seen in one of the previous presentations that we've got the product experience, customer experience, and pricing experience. We can have a great product, but if we service them like crap, we're not going to have a great product or a great company, to be honest. Having that customer experience is really important for us.

Bernie Ridgeway
Executive Chair, Artrya

Okay. Another question.

Peter Raven
Private Investor

Don't reach in there, [Michael]

Helen Kurincic
Non-Executive Director, Artrya

What are you doing for the online?

Bernie Ridgeway
Executive Chair, Artrya

What are you doing for the online guys?

Peter Raven
Private Investor

I am Peter Raven. I am guest here. I am broken, but I just want to ask some questions. How have you incorporated the AI into your technology, and what is the differentiator of what you are doing to, say, your competition and things like that?

Bernie Ridgeway
Executive Chair, Artrya

Yeah.

John Konstantopoulos
CEO, Artrya

Our competition, when they started their companies a few years back, they were focused heavily on making sure that the blood flow, let us take HeartFlow as an example, the blood flow was accurate. The way they did that was use a certain level of AI to do pre-processing of the scans, and then run the blood flow analysis, and then send it on to people to make sure that it is cleaned up and then accurate. Because that was cleared by the FDA, for them to change that, they would have to effectively change their whole architecture to do something what we have done, and go through a whole process all over again.

We are in the fortunate position as that fast, innovative follower where we have seen what others have done and we have figured out better ways to do that, which is we have made sure that our architecture is a lot more parallelized so that we can process and do all the real-time work that we have got in the software. The AI looks at the scan and extracts the coronary vessels, it extracts the disease, it quantifies the disease, it characterizes where the disease is, and then that brings that into that single platform. Now, we have got about 30, Phil, what is it? 37 patents, I think we have at the moment. So, we have got about 37 patents that cover varying levels of AI analysis, blood flow analysis, the disease assessment, as well as some of the unique things that we have as well.

But going forward, our focus is to use that real-time architecture, the real-time AI analysis in all the other modules that we've got as well. It does set a really good base for us to keep on building new modules in there.

Bernie Ridgeway
Executive Chair, Artrya

Can I just add to that, Peter? We're the only player out there with a fully cloud-based offering. That real time, essentially real time, it's in that sort of five to 10 minutes, that's considered real time in the healthcare sector. Now, we'll gradually bring that down over time, but we're the only cloud-based provider that's fully scalable. When you say, What are our competitors doing? First of all, that's a key differentiator. We use this, they've always got this, their system relies on a human intervention, so we call it human in the loop, where, as John said, that scan gets sent back to their center where they analyze it, do whatever, and you might get it back in 24 hours, 48 hours, days, or even, we've heard, even weeks. With ours, it's essentially real time.

While the clinician has the patient in the rooms, that clinician can then give the patient the results and walk out of there with a treatment program.

Jacque Sokolov
Non-Executive Director, Artrya

And that's—

Bernie Ridgeway
Executive Chair, Artrya

It is a massive differentiator.

Jacque Sokolov
Non-Executive Director, Artrya

That process time will only get faster.

Bernie Ridgeway
Executive Chair, Artrya

Yeah.

John Konstantopoulos
CEO, Artrya

Yeah, I think, just on that, I mean, everybody has asked this in the past, I mean, all these AI models coming out, are they going to differentiate us? I mean, we are an AI company. We are disrupting ourselves the whole time as well, so we are consistently innovating by ourselves. When I see what this team does upstairs, it is mind-blowing the type of work that they do. We saw something at the board earlier today, which the things that they try and figure out and solve to do things better, faster, more clinically relevant to doctors and patients is something that we heavily focused from an innovation and R&D perspective here in the company. That is something we are continuously investing in, is making sure that we are staying ahead of that as well.

Bernie Ridgeway
Executive Chair, Artrya

On SCF, for example, no one has done what we are doing. Pushing on with that, we are confident of getting it through the FDA. That gives us a massive differentiation in the marketplace. All right. That seems like the end of questions. If there are no more questions, then I thank you for your attendance, and that concludes the meeting. Thank you.

Jacque Sokolov
Non-Executive Director, Artrya

Thank you.

John Konstantopoulos
CEO, Artrya

Sorry, Bernie. Just a quick It's worth Clayton why he joined, because I don't think many of the shareholders heard yet why Clayton joined us.

Bernie Ridgeway
Executive Chair, Artrya

I think it'd be important. Yeah, it'd be good for them to hear.

Yeah, go for it.

Clayton Hatch
CFO, Artrya

It seems I haven't spoken yet, so hi. Just sitting here minding my own business, but thanks, John. I appreciate that. Yeah, I did join the company start of September, coming from a company, Pro Medicus, that has been 15 years, well, smaller when I started, and they're bigger now, that has commercialized in the U.S. So, to some of the questions today around the pace, we are moving at a quicker pace than what I saw at Pro Medicus. That's not to say they didn't do things slowly. It is the U.S. healthcare system. I think Jeff and Jacque could appreciate that as well, coming from the U.S. The way that they move and make decisions, I think having five customers now on board has been testament to that.

The one thing that Pro Medicus has done, and I think is key to us, and to John's point is, they haven't lost a customer in 15 years. So, 0% churn. If we build up the company in the right way, that's exactly what we need to do. The main reason why I looked at joining the organization is, one, the U.S. commercialization. Secondly, I had seen that this was a platform play, not a single point solution. Having come from a platform company, Pro Medicus, that was real key to me joining the organization. Secondly, John was a great guy. [audio distortion] organization. It's treating, an area, as John mentioned, really important area of healthcare. It's a great company to work for, so, yeah, I was really excited to join.

Bernie Ridgeway
Executive Chair, Artrya

Well, with that, I'll close the meeting. Thank you.